Modulation of light delivery in photodynamic therapy of brain tumours

Citation
Sh. Tudge et al., Modulation of light delivery in photodynamic therapy of brain tumours, J CL NEUROS, 6(3), 1999, pp. 227-232
Citations number
52
Categorie Soggetti
Neurology
Journal title
JOURNAL OF CLINICAL NEUROSCIENCE
ISSN journal
09675868 → ACNP
Volume
6
Issue
3
Year of publication
1999
Pages
227 - 232
Database
ISI
SICI code
0967-5868(199905)6:3<227:MOLDIP>2.0.ZU;2-K
Abstract
This study was performed to determine whether modulation of light delivery could improve tumour kill in photodynamic therapy (PDT) of brain tumours, a s optimal dosimetry has not been fully established. One hundred and sixty-f ive adult Wistar rats were treated, of which 70 had an implanted C6 cerebra l glioma. Haematoporphyrin derivative (HpD) was injected at doses between 0 and 20 mg/kg, 24 h prior to irradiation with 630 nm laser light. The total energy dose was Varied from 0 to 1200 J/cm(2), with fluence rates of 625, 3125 or 9375 mW/cm(2). In some studies, the light delivered at 3125 mW/cm(2 ) was divided into 10 fractions of approximately 13 s, with refractory inte rvals of 60 s. The most striking finding was that HpD was much more potent than previously reported. All doses greater than 1.0 mg/kg resulted in norm al brain damage with light doses above 50 J/cm(2). However, at 1.0 mg/kg, s ignificant normal injury was not apparent until 1200 J/cm(2). Failure of dr ug-light dose reciprocity indicated that photobleaching occurred, protectin g normal tissue. Selective tumour kill was observed to 2.2 mm depth (SE +/- 0.44 mm). Using lower power or fractionated light did not improve tumour k ill and normal tissue injury occured with fluence rates of 9375 mW/cm(2). I n conclusion, the doses of HpD currently used in clinical brain tumour tria ls may be too high to achieve selective tumour kill. Higher light fluence r ates allowed shorter intraoperative irradiation times with no loss of effic acy. Photodynamic therapy continues to demonstrate potential as an effectiv e treatment for local control of cerebral lesions.